Navigation Links
Antibacterial Drugs: World Market Prospects 2012-2022
Date:12/27/2011

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Antibacterial Drugs: World Market Review

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

2. An Introduction to Bacteria, Bacterial Infections and Antibacterial Drugs

2.1 Bacteria and Bacterial Infections

2.1.1 Bacteria

2.1.2 Clinically Important Bacteria

2.1.3 Bacterial Infections

2.1.3.1 Bacteria's Infectious Activity

2.2 Antibacterial Drugs

2.2.1 A History of Antibacterial Drugs

2.2.1.1 Penicillin

2.2.1.2 Other Key Steps in the History of Antibacterial Drugs

2.2.2 Mechanisms of Action for Antibacterial Drugs

3. The Antibacterial Drugs Market 2012-2022

3.1 The Antibacterial Drugs Market 2010-2011

3.2 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022

3.2.1 Generic Competition

3.2.2 Prescribing Antibacterial Drugs

3.2.3 Bacterial Resistance

3.2.4 R&D Pipeline Will Restrain Growth?

3.3 Cephalosporins Submarket 2010-2011

3.3.1 Cephalosporins Submarket: Revenue Forecast 2012-2022

3.4 Penicillin Submarket 2010-2011

3.4.1 Penicillins Submarket: Revenue Forecast 2012-2022

3.5 Fluoroquinolone Submarket 2010-2011

3.5.1 Fluoroquinolones are Linked with Side Effects

3.5.2 Fluoroquinolone Pipeline 2011

3.5.3 Fluoroquinolone Submarket: Revenue Forecast 2012-2022

3.6 Macrolide Submarket 2010-2011

3.6.1 Dificid: A New Macrolide

3.6.2 Macrolide Submarket: Revenue Forecast 2012-2022

3.7 Carbapenems Submarket 2010-2011

3.7.1 Doribax (Doripenem, Ortho-McNeil/Shionogi)

3.7.2 Carbapenems Submarket: Revenue Forecast 2012-2022

3.8 Other Antibacterial Drugs Submarket 2010-2011

3.8.1 Vibativ

3.8.2 Other Antibacterial Drugs Submarket: Revenue Forecast 2012-2022

4. Leading Antibacterial Drugs: Market Prosp
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
2. Reportlinker Adds The Antibacterials Market Outlook to 2016
3. Reportlinker Adds Forecast Insight: Antibacterials
4. FDA Clears Single-Use Antibacterial Surgical Respirator
5. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
6. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
7. Trius Doses First Patient in Antibacterial Phase 2 Trial
8. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
9. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
10. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
11. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the developer ... metabolic diseases and other gastrointestinal disorders, today announced that ... the Board of Directors, effective July 31, 2015.  Ms. ... the 2018 annual meeting or until her successor is ... in an executive capacity in the healthcare industry for ...
(Date:8/2/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... discover and develop antisense therapies for cardiovascular, metabolic ... a broad existing relationship between the two companies ... areas using novel RNA-targeted treatments. It also enables ... technology to diseases of the kidney. ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4
... statins for only five weeks at,400 mg/week lowered ... with similarly favorable effects on other,atherogenic lipids, NEW ... Isis Pharmaceuticals, Inc. announced new,results from its Phase ... presented today at the of Cardiology,Annual Scientific Session ...
... Only Illinois Site in Trial , CHICAGO, March ... adult stem cell therapy, Provacel™,experienced a lower number ... significant improvements in heart, lung and,global function compared ... Phase I study data presented at the American ...
Cached Medicine Technology:Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 2Heart Attack Patients Treated With Novel Stem Cell Therapy,Experience Significant Improvement in Heart and Lung Function 3
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay $56.9 million to ... a claimant alleged to have suffered an arterial blood clot including stroke and heart ... Yasmin and Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions ... health care costs. , Annually, more than 8.6 million adverse drug events ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social ... , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive ... – an organization whose mission is to develop technology for the sake of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
Breaking Medicine News(10 mins):Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... recovering from heart problems, but have depression take longer ... a treadmill stress test, according to a new study ... Dr. Joel W. Hughes, of Kent State University, Ohio, ... recover from the stress test have increased mortality risk. ...
... to naught. Apart from the ordeal of suffering a naughty child, ... an awfully expensive proposition for the parents and for the society ... to the parents, the NHS, social services and schools to the ... ,But the most part of the ordeal is faced by the ...
... currently on a visit to Riyadh, has declared that ... center for the All India Engineering Entrance Examination (AIEEE) ... of equivalence of degrees will cease to be a ... Muslim University Old Boys' Association (AMUOBA), which had organised ...
... Karen Johnstone, 28, was suffering from Deep Vein Thrombosis since ... away after doctors told her that she no longer suffered ... a blood clot that had formed in her legs moved ... her lungs. ,Kathy and Norman, Karen’s parents, absolutely devastated ...
... on the worries experienced by long-term survivors reveals the ... treatment//, a second cancer and a shortened life will ... the thoughts of approximately one-third of long-term, older-adult cancer ... Survivor Research Project reports. ,It may ...
... increases the concentration, abstract reasoning and verbal skills in ... must be interpreted with caution//. ,Mark Espeland ... Center in the US studied more than 7,000 older ... amount of alcohol have slightly higher levels of mental ...
Cached Medicine News:Health News:After Cancer Treatment Worry Continues – Researchers Find 2Health News:After Cancer Treatment Worry Continues – Researchers Find 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: